Skip to search formSkip to main contentSkip to account menu

onartuzumab

Known as: Anti-MET Monoclonal Antibody MetMAb, MetMAb 
A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Narrower (1)

OA-5D5

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.
2015 Background: The phase II GO27819 study assessed the monovalent MET inhibitor, onartuzumab, plus the anti-VEGF antibody… 
Review
2014
Review
2014
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
The MET/hepatocyte growth-factor (HGF) signaling pathway plays a key role in the processes of embryogenesis, wound healing, and… 
2013
2013
MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or…
TPS4155 Background: Dysregulation of the HGF/MET pathway in patients with gastroesophageal cancer (GEC) is associated with… 
2013
2013
Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
Purpose: We characterized the pharmacokinetics of onartuzumab (MetMAb) in animals and determined a concentration–effect… 
Review
2012
Review
2012
Targeting the Met pathway in lung cancer
Dysregulation of Met signaling has been implicated in the initiation, progression and metastasis of human cancers, and therefore… 
2012
2012
The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer…
TPS7616 Background: Increased Met signaling is associated with poor prognosis in NSCLC and can result in acquired resistance to… 
2011
2011
Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with…
Background: The receptor tyrosine kinase Met and/or its ligand, hepatocyte growth factor (HGF), are frequently over-expressed in… 
2008
2008
411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally…
2008
2008
Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors
1336 Crosstalk between EGFR and c-Met has been implicated in a number of biological systems. In tumors, interactions between… 
2008
2008
556 POSTER MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)